In summary, using a robust quantitative analysis technique, we have shown that an alternate cut-point for PD-L1 expression (tumor PD-L1 ≥ 5%) is associated with OS in patients with anal cancer treated with curative-intent CRT. The gene discussed is CD274; the disease is anal carcinoma.